# AURA3 (NCT02151981)

> AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Indication: EGFR T790M-positive advanced non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02151981
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Anticancer Treatment
- Interventions: Chemotherapy; Cross-over to Osimertinib
- Enrollment: 421
- Primary outcome: Progression Free Survival (PFS) by Investigator Assessment

## Indexed commentary on AURA3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 23 posts on X
- 1 YouTube video
- 1 podcast episode

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=aura3-nct02151981

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02151981", "email": "<work email>"}; the inbox owner confirms by the emailed link.